PharmiWeb.com - Global Pharma News & Resources
23-Mar-2020

Biofrontera AG: Biofrontera AG withdraws subscription offers for mandatory convertible bonds

Biofrontera AG / Key word(s): Corporate Action
Biofrontera AG: Biofrontera AG withdraws subscription offers for mandatory convertible bonds

23-March-2020 / 15:45 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad-hoc Release pursuant to Art. 17 MAR

Biofrontera AG withdraws subscription offers for mandatory convertible bonds

Leverkusen, Germany, March 23, 2020 - On February 26, 2020, the Management Board resolved to issue up to 1,600,000 of the 0.5% qualified subordinated mandatory convertible bonds 2020/2024 (ISIN: DE000A254RS9) ("Bonds 2020/2024") with a nominal value of EUR 5.00 each and a total nominal value of up to EUR 8,000,000 as well as up to 1,600,000 of the 1.00 % qualified subordinated mandatory convertible bonds 2020/2026 (ISIN: DE000A254RR1) ("Bonds 2020/2026") with a nominal value of EUR 5.00 each and a total nominal value of up to EUR 8,000,000.

By announcements in the Federal Gazette (Bundesanzeiger) on February 28, 2020, in order to avoid exclusion from subscription rights, the shareholders or holders of subscription rights were requested to exercise their subscription rights for the Bonds 2020/2024 and for the Bonds 2020/2026 during the period from March 02, 2020 to March 17, 2020 during normal business hours.

As capital market conditions had changed as a result of the coronavirus crisis, the Management Board had resolved on March 12, 2020 to extend the subscription period for the Bonds 2020/2024 and for the Bonds 2020/2026 until March 31, 2020.

Due to further substantially changed conditions since March 12, 2020 as a result of the coronavirus crisis, the Management Board today resolved not to offer the Bonds 2020/2024 and the Bonds 2020/2026 based on the previously determined conditions.

The subscription offer for the Bonds 2020/2024 and the subscription offer for the Bonds 2020/2026 are therefore withdrawn and will not be completed. A respective announcement will be published in the Federal Gazette shortly.


Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611

Contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
E-mail: ir@biofrontera.com


23-March-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: ir@biofrontera.com
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 1004219

 
End of Announcement DGAP News Service

Editor Details

Last Updated: 23-Mar-2020